Engage Biologics Inc. (“Engage”), a preclinical biotechnology company pioneering non-viral DNA delivery, announces that it has been acquired by Eli Lilly and Company (“Lilly”). Engage is developing the Tethosome platform, a novel non-viral DNA delivery system designed to overcome key limitations in DNA delivery, including potency, tolerability, and redosability. The platform combines engineered DNA payloads with lipid nanoparticle delivery and an mRNA-encoded proprietary Tethosome technology designed to enhance localization and increase expression. Under the terms of the agreement, Lilly acquired Engage for up to $202 million in cash.
Read the full article: Engage Bio Acquired by Lilly to Accelerate Development of Non-Viral Genetic Medicines //
Source: https://www.businesswire.com/news/home/20260520932076/en/Engage-Bio-Acquired-by-Lilly-to-Accelerate-Development-of-Non-Viral-Genetic-Medicines